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Abstract
Introduction: Fulvestrant shows dose-dependent biological activity. Greater estrogen-receptor (ER) blockade may
feasibly be achieved by combining fulvestrant with anastrozole. This pre-surgical study compared fulvestrant plus
anastrozole versus either agent alone in patients with ER-positive breast cancer.
Methods: In this double-blind, multicenter trial, 121 patients received fulvestrant 500 mg on Day 1 plus
anastrozole 1 mg/day for 14 to 21 days (F + A); fulvestrant plus anastrozole placebo (F); or fulvestrant placebo plus
anastrozole (A), 2 to 3 weeks before surgery. ER, progesterone-receptor (PgR) and Ki67 expression were determined
from tumor biopsies before treatment and at surgery.
Results: A total of 103 paired samples were available (F, n = 35; F+A, n = 31; A, n = 37). All treatments significantly
reduced mean ER expression from baseline (F: -41%, P = 0.0001; F + A: -39%, P = 0.0001; A: -13%, P = 0.0034).
F and F + A led to greater reductions in ER versus A (both P = 0.0001); F + A did not lead to additional reductions
versus F. PgR and Ki67 expression were significantly reduced with all treatments (means were -34% to -45%, and
-75% to -85%, respectively; all P = 0.0001), with no differences between groups.
Conclusions: In this short-term study, all treatments reduced ER expression, although F and F + A showed greater
reductions than A. No significant differences were detected between the treatment groups in terms of PgR and
Ki67 expression. No additional reduction in tumor biomarkers with combination treatment was observed,
suggesting that F + A is unlikely to have further clinical benefit over F alone.
Trial registration: Clinicaltrials.gov NCT00259090.
Introduction
Fulvestrant is an estrogen-receptor (ER) antagonist with
no known agonist effects. It binds, blocks and accelerates
degradation of the ER, leading to dose-dependent reduc-
tions in cellular ER and proliferation-related antigen Ki67
[1,2]. Unlike tamoxifen, which increases progesterone-
receptor (PgR) expression, fulvestrant also induces dose-
dependent reductions in PgR expression [1]. Fulvestrant-
mediated reductions in tumor biomarkers are indicative of
anti-estrogenic and anti-proliferative effects [1,3,4], and
may be useful as surrogate endpoints of clinical efficacy.
The registration trials of fulvestrant (0020 and 0021) pro-
vided the first indication of its dose-related anti-tumor
activity. Fulvestrant 250 mg was not significantly different
from the aromatase inhibitor (AI) anastrozole, 1 mg daily,
for the primary endpoint of time to progression in the
treatment of postmenopausal women with advanced
breast cancer who had recurred or progressed following
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prior endocrine therapy [5-7]. Although these trials initi-
ally incorporated a fulvestrant 125 mg treatment arm, an
interim analysis showed insufficient evidence of clinical
activity (no objective tumor responses and numerically
lower time to progression (TTP)), and this arm was dis-
continued [5-8].
As ER down-regulation appears to be dose-dependent, it
was hypothesized that ER antagonism may be enhanced
by raising fulvestrant steady-state plasma concentrations
to a higher level than those achieved by the 250 mg/
month regimen [1,2]. In addition to this, the biological
activity of fulvestrant 500 mg (fulvestrant 500 mg/month
plus 500 mg on Day 14 of Month 1) versus 250 mg
(fulvestrant 250 mg/month) was investigated in the
Neoadjuvant Endocrine therapy for Women with Estro-
gen-Sensitive Tumors (NEWEST) study. The higher ful-
vestrant dose was associated with significantly greater
down-regulation of Ki67 at Week 4 (primary endpoint), as
well as similar reductions in ER and PgR protein expres-
sion. The higher fulvestrant dose also produced numeri-
cally higher tumor response rates [9].
The clinical activity of fulvestrant 500 versus 250 mg
was further compared in the phase III COmparisoN of
Faslodex In Recurrent or Metastatic breast cancer
(CONFIRM) study, in which a significantly longer TTP
was reported with the 500 mg dose (hazard ratio (HR) =
0.80; P = 0.006) [10].
Other questions posed were, first, whether a 500 mg
regimen might be better than an AI, given that fulves-
trant 250 mg had been equivalent to anastrozole; and
second, whether there was any value in combining an AI
and fulvestrant, either at the 250 or 500 mg dose. The
rationale for the latter approach was that combining ful-
vestrant with an estrogen-lowering agent may lead to
enhanced ER blockade and anti-tumor activity. This pos-
sibility was examined in the Fulvestrant loading dose and
Anastrozole in Combination Trial (FACT), in which
patients at first relapse received either a loading-dose
regimen of fulvestrant (500 mg on Day 0; 250 mg on
Days 14 and 28; then 250 mg monthly thereafter) plus
anastrozole (1 mg daily), or anastrozole alone [11]. There
were no significant differences between the two groups
in the primary endpoint of TTP (HR = 0.99; P = 0.91) or
in any of the secondary endpoints [11]. Critically, there
was no underlying biomarker study, and FACT did not
compare the combination of fulvestrant plus anastrozole
versus fulvestrant alone. In the recently reported SWOG
S0226 study, Mehta and colleagues report that the com-
bination of the fulvestrant 250 mg loading-dose regimen
with anastrozole was associated with improved progres-
sion-free survival versus anastrozole alone in postmeno-
pausal women with untreated advanced breast cancer,
indicating that the combination treatment may be effec-
tive in some patients [12].
This pre-surgical study was thus designed to compare
the biological activity and safety of fulvestrant 500 mg
versus anastrozole versus the combination (fulvestrant
500 mg plus anastrozole) as pre-surgical treatment in
women with ER-positive breast cancer. This study was
conducted in parallel with the Fulvestrant fIRst-line
Study comparing endocrine Treatments (FIRST) phase II
trial, which compared the clinical efficacy of fulvestrant
500 mg versus anastrozole for the first-line treatment of
advanced hormone receptor-positive breast cancer [13].
The primary endpoint of FIRST was clinical benefit rate
(CBR), which was numerically but not statistically greater
for fulvestrant 500 mg compared with anastrozole (72.5%
versus 67.0%), with the odds ratio (OR = 1.30; P = 0.386)
in favor of fulvestrant. The secondary endpoint (TTP)
was, however, significantly longer for fulvestrant 500 mg
(median TTP not reached for fulvestrant v 12.5 months
for anastrozole; HR = 0.63; P = 0.0496) [13]. The superior
clinical efficacy seen in FIRST makes the present biomar-
ker study even more important, both for its potential to
provide a biological rationale for why fulvestrant 500 mg
might be better than anastrozole and also to provide an
insight into whether adding anastrozole to fulvestrant
500 mg might be a treatment strategy worth pursuing.
Materials and methods
Study design and patients
Trial 0057 was a phase II, double-blind, randomized, mul-
ticenter trial (9238IL/0057; NCT00259090). Patients were
postmenopausal women (>12 months since the last men-
strual period and/or castrate levels of follicle-stimulating
hormone (>40 IU/liter)) with histologically or cytologically
confirmed ER-positive, primary breast cancer (T1, T2 or
T3). Patients had to be fit for surgery within one month
and have a tumor large enough to provide sufficient biopsy
samples. Patients were excluded from the trial if they had
evidence of metastatic disease; received prior endocrine
treatment for breast cancer, prior neoadjuvant chemother-
apy or prior radiotherapy to the primary tumor; abnormal
laboratory values; any severe concurrent condition;
received hormone replacement therapy within the past
four weeks; a history of disease affecting steroid metabo-
lism; a history of bleeding diathesis, thrombocytopenia or
a need for long-term anti-coagulant therapy; risk of
human immunodeficiency virus, hepatitis B or hepatitis C
transmission; evidence of severe systemic disease; baseline
hematology or clinical chemistry outside the normal
range; or any other reason that could jeopardize the proto-
col. Prior to surgery of curative intent, patients were ran-
domized 1:1:1 to receive a single administration of
fulvestrant 500 mg (2 × 250 mg on Day 1 via intramuscu-
lar injection) plus anastrozole (1 mg orally once daily for
14 to 21 days), or fulvestrant 500 mg plus anastrozole pla-
cebo or anastrozole plus fulvestrant placebo (Figure 1).
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All patients provided written informed consent. The
study was performed in accordance with the Declaration
of Helsinki and was consistent with International Confer-
ence on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH)
Good Clinical Practice. The study protocol, patient con-
sent forms and information sheets were approved by the
relevant independent ethics committee (Nottingham
Ethics Committee 1; ethics reference number EC02/170)
and institutional review boards.
Study assessments
The primary endpoints were treatment effects on ER, PgR
and Ki67 expression in tumor biopsy samples obtained
pre-treatment and during surgery. These three tumor bio-
markers were considered equally important indicators of
fulvestrant activity. Their expression was determined by
immunohistochemistry on sections of formalin-fixed, par-
affin-embedded tissue, assaying matched sequential biopsy
samples together for each patient. Antigen retrieval for ER
and PgR was performed by pressure cooking in 0.01 M
sodium citrate buffer, pH 6.0. Optimal ER staining was
achieved with primary antibody clone 6F11 (NCL-ER-
6F11, Novocastra, Newcastle upon Tyne, UK). For maxi-
mal PgR staining sensitivity, sections were co-incubated
with primary antibody clones 636 (M3569, Dako Ltd.,
Cambridge, UK) and 16 (VP-P976, Vector Laboratories,
Burlingame, CA, USA). Clone MIB-1 anti-Ki67 antibody
(M7240, Dako Ltd.) was employed following microwave
antigen retrieval in 0.01 M citric acid. The EnVision sec-
ondary antibody detection kit (Dako Ltd.) was used in all
instances with DAB chromogen (Dako Ltd.). All biomar-
ker measurements were performed at the Tenovus Centre
for Cancer Research by two research scientists (JMWG
and PF) experienced in H-score measurement. At least
five fields were viewed simultaneously using a light micro-
scope at x20 magnification and a representative field was
then assessed by both researchers at x40 magnification
using a dual viewing attachment. All samples consisted of
at least 100 tumor epithelial cells. Reference to equivocal
samples from a pathologist was available when required.
As described previously [1], the percentage of ER- or
PgR-positive tumor epithelial cell nuclei in each staining
category (that is, negative -/-; very weak +/-; weak +; mod-
erate ++; strong +++) were recorded for each sample by
consensus of the two assessors. Results were expressed as
the H-score, where H-score = ((0.5 × % +/-) + (1 × +) +
(2 × % ++) + (3 × % +++)), with a range of 0 to 300. Ki67
index was also assessed by light microscopy and consensus
results for each sample were expressed as the percentage
of positively stained tumor epithelial cells, as described
previously [1]. To monitor assay performance, breast-can-
cer samples of known ER, PgR or Ki67 content were
included as positive controls in every assay.
Rates of breast-conserving surgery, clinical response
rate and pathological response rates were not collected
prospectively, as these data were not expected to provide
meaningful results in this short-term study.
Fulvestrant 500 mg on Day 1
+ anastrozole placebo
for 14-21 days
(n = 35)
Fulvestrant 500 mg on Day 1
+ anastrozole 1 mg orally
for 14-21 days
(n = 31)
Anastrozole 1 mg orally
 for 14-21 days
+ fulvestrant placebo on Day 1
(n = 37)
Extended (n = 18)
• Insufficient tumor tissue to
   allow paired analysis (n = 13)
• Treated to surgery period too
   long (n = 3)
• Consent withdrawal (n = 1)
• ER-negative status (n = 1)
Surgery 
(n = 35)
Surgery 
(n = 31)
Surgery 
(n = 37)
121 patients
randomized
1:1:1
Biopsy
Day 1
Days 15-22
Pre-randomization
Randomization
Figure 1 Study design. ER, estrogen receptor.
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Tolerability was a secondary endpoint and was
assessed by recording the incidence of adverse events
(AEs) following treatment and surgery. AEs were classi-
fied according to the Medical Dictionary for Regulatory
Activities.
Statistical analysis
Based on data from our previous fulvestrant study [1],
sample size calculations indicated that 30 patients per arm
were needed to detect relevant differences between treat-
ment groups with 80% power (38.1 for ER; 21.5 for PgR;
and 64.4 for Ki67), using a two-sided significance level of
5%. This is consistent with other similar studies, in which
patient numbers are usually small. For the analysis of
Ki67, the detectable ratio was 0.644 and so the study was
powered to detect a difference between changes of, for
example, -75% and -91%. The study was not powered to
detect smaller changes between treatment groups, and
sample sizing was a balance between the ability to detect
differences between arms and the challenge of patient
recruitment across the four centers. Analysis of covariance
(ANCOVA), with terms in the model for treatment and
center, and baseline values as a covariate, was performed
to compare the mean H-score post-treatment. If the test
for overall treatment effect was significant at the 5% level,
then all pairwise comparisons were made (this is Fisher’s
protected Least Significant Difference test). The overall
treatment effect and pairwise comparison calculations
were also performed using a Bonferroni correction, to
allow for having three primary endpoints. For Ki67, the
data showed evidence of non-normality, so all values were
log-transformed (after adding a constant of 1) and the
results back-transformed to the original scale. ANCOVA
was also used to assess differences between mean H-score
at baseline and post-treatment within each treatment
group using individual change values. As an aid to inter-
pretation, mean changes from baseline have been con-
verted to percentage of initial staining (by dividing mean
changes by the overall mean at baseline).
The number of tumors that showed a reduction in ER
and PgR was also deemed to be of interest. In a descrip-
tive analysis, the number of individual patients with
reductions from baseline in ER or PgR H-score was
tabulated.
Results
Patients
In total, 121 patients were randomized at four centers in
the UK and 18 patients were omitted from the final ana-
lysis (Figure 1). The first patient was randomized on 5
January 2006 and the final patient completed the trial on
9 October 2008. Paired samples from 103 patients were
available for analysis: 35 patients treated with fulvestrant
500 mg alone, 31 patients treated with fulvestrant
500 mg plus anastrozole, and 37 patients treated with
anastrozole alone. Mean age was 65.7 years (range 50 to
88 years) and the majority of patients had grade-2 tumors
(Table 1).
Tumor biomarker expression
ER H-scores were significantly reduced from baseline by
-41% in the fulvestrant 500 mg group (P = 0.0001),
-39% in the fulvestrant 500 mg plus anastrozole group
(P = 0.0001) and -13% in the anastrozole group (P =
0.0034) (Table 2).
Fulvestrant 500 mg alone and the combination of ful-
vestrant 500 mg plus anastrozole led to greater reduc-
tions in ER H-score compared with anastrozole alone
(both P = 0.0001) (Figures 2a and 3a). There was no sig-
nificant difference in ER H-score reductions between
fulvestrant 500 mg plus anastrozole versus fulvestrant
500 mg alone (P = 0.72).
Nine patients with a PgR H-score of 0 at baseline were
omitted from the analysis. PgR H-scores were signifi-
cantly reduced from baseline by all treatments: -34%
with fulvestrant 500 mg, -45% with fulvestrant 500 mg
plus anastrozole and -37% with anastrozole alone (all
P = 0.0001) (Table 2). There were no significant
between-treatment differences in reduction of PgR
(Figures 2b and 3b). Similarly, Ki67 expression (assessed
for all patients) was significantly and substantially
reduced from baseline in all groups (-75%, -81% and
-85% for fulvestrant 500 mg alone, fulvestrant 500 mg
plus anastrozole, and anastrozole alone, respectively; all
P = 0.0001) (Table 2), with no significant differences
between treatments (Figures 2c and 3c). The residual
level of proliferation after any of these treatments was
invariably low, reflected in the post-treatment mean
index levels (Table 2).
The significance levels for reduction in ER and PgR
H-score and Ki67 expression remained unchanged when
the Bonferroni correction was applied to allow for hav-
ing three primary endpoints (that is, using a significance
level of P <0.017).
When changes in ER H-score were assessed, 86% of
patients in the fulvestrant 500 mg group and 77% of
patients in the fulvestrant 500 mg plus anastrozole
group experienced a decrease in H-score of >20 from
baseline. Fewer patients in the anastrozole group (35%)
experienced a decrease in H-score of >20 from baseline.
The percentage of patients exhibiting reductions in PgR
H-scores was similar across the three groups; 64%, 75%
and 73% of patients in the fulvestrant 500 mg, fulves-
trant 500 mg plus anastrozole, and anastrozole treat-
ment groups, respectively, experienced a reduction in
PgR H-score of >20 from baseline.
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Tolerability
The incidence of AEs was similar in all treatment groups,
with 68% of the patients experiencing at least one AE with
fulvestrant 500 mg, 68% with fulvestrant 500 mg plus ana-
strozole and 73% with anastrozole alone. The most com-
mon AE in patients who received fulvestrant 500 mg alone
or anastrozole alone was hot flash (18% and 20%, respec-
tively) (Table 3). In the fulvestrant 500 mg plus anastro-
zole group, the most frequent AEs were headache (10%)
and pain in an extremity (10%).
There were no serious AEs (SAEs) in the fulvestrant
group, three SAEs in the fulvestrant 500 mg plus anastro-
zole group (atrial fibrillation, hospitalization for right
mastectomy and procedural complication due to skin
flap failure), and two SAEs in the anastrozole group (sub-
cutaneous abscess and pancytopenia). No SAEs were
considered by the investigator to be treatment-related.
Two patients in the anastrozole group withdrew from the
study due to AEs: pancytopenia (SAE) and cardiac
arrhythmia (non-SAE).
Discussion
Previous neoadjuvant studies have compared selective ER
modulators, such as tamoxifen, with AIs, such as anastro-
zole [14] and letrozole [15]. To our knowledge, this study
is the first to compare directly, in a randomized trial, the
biological activity of a selective ER antagonist, such as
fulvestrant, versus an AI in a pre-surgical setting. Further-
more, the dose of fulvestrant used was 500 mg, which is
now the recommended dose in many countries. This
study is also the first to compare the activity of fulvestrant
500 mg with and without anastrozole. Following treat-
ment, ER H-scores were significantly reduced from base-
line in all groups; however, there were greater reductions
Table 1 Patient demographics
Fulvestrant
500 mg
Fulvestrant
500 mg + anastrozole 1 mg
Anastrozole 1 mg
n 35 31 37
Age, years
Mean 67.9 64.2 64.8
Standard deviation 8.5 10.2 8.7
Tumor gradea
1 8 9 8
2 23 16 25
3 4 4 4
aTwo patients in the fulvestrant 500 mg plus anastrozole group had bilateral breast tumors of differing grades and are not included in the above baseline grade
table.
Table 2 Summary of ER, PgR and Ki67 labeling index data
Fulvestrant
500 mg
Fulvestrant
500 mg + anastrozole 1 mg
Anastrozole 1 mg
ER
n 35 31 37
Pre-treatment mean H-score 187.7 184.2 192.2
Post-treatment mean H-score 111.9 115.8 164.2
Change (post-treatment), % (SEM) -41 (4) -39 (5) -13 (4)
Comparison versus baseline P = 0.0001 P = 0.0001 P = 0.0034
PgR
n 33 28 33
Pre-treatment mean H-score 145.7 141.7 157.6
Post-treatment mean H-score 97.9 81.1 93.8
Change (post-treatment), % (SEM) -34 (6) -45 (7) -37 (6)
Comparison versus baseline P = 0.0001 P = 0.0001 P = 0.0001
Ki67
n 35 31 37
Pre-treatment mean index 17.1 17.8 16.2
Post-treatment mean index 4.2 3.3 2.6
Change (post-treatment), % (SEM) -75 (9) -81 (7) -85 (5)
Comparison versus baseline P = 0.0001 P = 0.0001 P = 0.0001
ER, estrogen receptor; PgR, progesterone receptor; SEM, standard error of the mean.
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with fulvestrant 500 mg and fulvestrant 500 mg plus ana-
strozole, compared with anastrozole alone. These findings
are entirely in accordance with the known mechanism of
action (MoA) of these two agents: fulvestrant as a selective
ER antagonist reduces tumor ER protein levels, while ana-
strozole reduces estradiol levels and, therefore, signaling
Fulvestrant
500 mg
Fulvestrant 500 mg
+ anastrozole 1 mg
Anastrozole
1 mg
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Figure 2 Mean change in pre- and post-treatment data. (a) ER H-score, (b) PgR H-score and (c) Ki67 labeling index. Where the overall tests
for treatment effect were not significant for total PgR H-score and Ki67 index, pairwise comparisons were deemed non-significant. Error bars
represent standard error of the mean. ER, estrogen receptor; NS, not significant; PgR, progesterone receptor.
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through the ER, but has little or no inhibitory effect on ER
levels. No additional reduction in ER expression was
observed when fulvestrant was combined with anastrozole,
compared with fulvestrant alone.
PgR expression levels were also significantly reduced
from baseline in all groups, but there were no significant
differences between fulvestrant plus anastrozole and
either agent alone. Again, this is in agreement with what
Fulvestrant
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Fulvestrant 500 mg
+ anastrozole 1 mg
Anastrozole
1 mg
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Mean change
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Figure 3 Scatter plots of individual pre- versus post-treatment data. (a) ER, (b) PgR and (c) Ki67. ER, estrogen receptor; PgR, progesterone
receptor.
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is known about the MoA of these drugs. PgR is an
estrogen-inducible protein, and removal of ER signaling
either by ER down-regulation or by blockade of estradiol
synthesis leads to reduced PgR levels. Similarly, either
MoA can decrease tumor cell proliferation. Although all
treatments impacted substantially on ER function and
proliferation, there was still some ER and PgR expres-
sion remaining in the post-fulvestrant treatment
biopsies.
The fact that combining two endocrine agents did not
result in increased reduction of PgR or Ki67 levels confirms
that they act with equivalent magnitude on the same signal-
ing pathway, but at different points. The reductions in
tumor biomarkers observed after anastrozole treatment are
also consistent with a recent randomized phase II study
which reports that anastrozole and letrozole led to equally
significant reductions in Ki67 expression [16]. Ellis and col-
leagues also reported that neoadjuvant treatment with an
AI was effective at improving clinical response rates and
surgical outcomes in postmenopausal breast cancer.
One of the strengths of this randomized pre-surgical
study is that double-blind procedures were extended
until all biomarker measurements had been made before
the treatment codes were broken.
The initial rationales for this study were that fulvestrant
500 mg might be biologically more potent than an AI and
also that a synergistic effect of combining the two could
be achieved. As fulvestrant competes with estradiol for ER
binding, reducing plasma estrogen levels using anastrozole
could feasibly increase fulvestrant-ER binding and increase
its efficacy. Using an intratumoral, aromatase-transfected
xenograft model, fulvestrant plus anastrozole was found to
delay tumor growth more effectively than either agent
alone [17]. In addition, further reduction in ER levels and
down-regulation of signaling proteins involved in the
development of hormonal resistance (for example, insulin-
like growth factor receptor 1 (IGF-1R), MAPK and AKT)
were observed with the combination treatment. Despite
these preclinical findings, our study found no biomarker
evidence that the combined treatment had enhanced bio-
logical activity in patients with breast cancer. These results
are in line with the FACT study, which reported no benefit
in clinical endpoints with the combination of a loading-
dose regimen of fulvestrant (250 mg) plus anastrozole ver-
sus anastrozole alone [11]. The recently described SoFEA
trial also failed to show any efficacy benefit for the combi-
nation of fulvestrant with an AI. Equivalent PFS was
demonstrated for fulvestrant (250 mg loading-dose regi-
men) plus anastrozole compared with fulvestrant alone in
postmenopausal patients with advanced breast cancer fol-
lowing progression on non-steroidal AIs [18]. However,
data from the SWOG S0226 study suggest that combina-
tion therapy as first-line treatment for advanced breast
cancer was associated with efficacy benefits in some
patients and may warrant further study [12]. For the pri-
mary endpoint, median PFS was 15.0 months for the com-
bination therapy (fulvestrant 250 mg loading-dose
regimen plus anastrozole) compared with 13.5 months for
anastrozole alone (HR = 0.80; P = 0.007). The reason for
the different outcomes in FACT and SWOG S0226 has
not been fully established. However, this may in part be
explained by the proportion of patients who had received
prior adjuvant endocrine therapy, which was somewhat
higher in the FACT trial. In a retrospective analysis of
those patients who had received previous adjuvant tamoxi-
fen treatment in the SWOG S0226 study (280/694; 40.3%),
median PFS was 13.5 months in the combination group
compared with 14.1 months in the anastrozole-alone
group (HR = 0.89; P = 0.37). In those patients naive to
prior tamoxifen therapy (414/694; 59.7%), median PFS was
17.0 months for the combination compared with 12.6
months for anastrozole alone (HR = 0.74; P = 0.006) [12].
Importantly, there was no fulvestrant-alone arm in SWOG
S0226 and so it is not possible from this study to establish
if the difference between the two arms is due to the fulves-
trant 250 mg loading-dose regimen being better than ana-
strozole in the first-line setting or due to the combination
of fulvestrant 250 mg and anastrozole.
Recently, a growing body of evidence has suggested
that fulvestrant 500 mg would offer efficacy benefits
over the existing 250 mg regimen. NEWEST was the
first study to demonstrate a higher biological activity
Table 3 Most common AEs occurring during the study
Patients experiencing an AE,a n (%)
Fulvestrant
500 mg
Fulvestrant
500 mg + anastrozole 1 mg
Anastrozole 1 mg
Hot flash 7 (18) 3 (8) 8 (20)
Headache 3 (8) 4 (10) 3 (8)
Pain in extremity 0 (0) 4 (10) 2 (5)
Constipation 3 (8) 1 (3) 2 (5)
Injection-site pain 2 (5) 1 (3) 3 (8)
Any AE 27 (68) 27 (68) 29 (73)
aData for the intent-to-treat population. One patient who received no treatment was excluded. AE, adverse event.
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(depletion of ER, PgR and Ki67) for fulvestrant 500 mg
versus 250 mg [9]. In addition, results from the CON-
FIRM study indicate greater clinical efficacy with the
500 mg regimen, without increased toxicity [10]. It,
therefore, appears that fulvestrant 500 mg results in
both increased biological activity and clinical efficacy.
The median day of biopsy across all patients in the pre-
sent study was Day 18 following a single fulvestrant
500 mg dose. However, previously published data suggest
that steady-state plasma fulvestrant levels are achieved
after approximately 28 days with the fulvestrant 500 mg
dose regimen (which also includes a 500 mg dose on Day
14) [8], and hence exposures following a single 500 mg
dose would be lower than those achieved at steady state.
This would suggest that the biological effect seen with a
single fulvestrant 500 mg dose may be an underestimate
compared with the fulvestrant 500 mg dose regimen
approved for clinical practice.
The biological results from the present study may shed
light on the results from FIRST, in which the secondary
endpoint of TTP was significantly longer for fulvestrant
500 mg over anastrozole (P <0.05) [13], an effect that was
maintained in prolonged follow-up data (HR = 0.66; P =
0.01) [19]. The primary endpoint showed a numerical, but
not statistically significant, difference in CBR. In the cur-
rent study, there was a greater decrease in ER (but not in
Ki67) for fulvestrant 500 mg compared with anastrozole.
The similar substantial initial decrease in proliferation
(that is, Ki67) would be in keeping with the initial CBRs
(de novo response) seen in FIRST. The improvement in
TTP in FIRST occurred after six months (due to prolonga-
tion of acquired resistance in tumors in which initial clini-
cal benefit was shown). In model systems, a mechanism
implicated in acquired resistance to endocrine therapy
(including estrogen deprivation) is cross-talk between ER
and other growth factor pathways (for example, HER2,
IGF-1R and downstream signaling kinases) [20-23]. The
activity of residual ER (or growth factor signaling ele-
ments) following fulvestrant treatment remain largely
unexplored, but the greater reduction in ER seen here
with fulvestrant might feasibly hinder instigation of such
cross-talk mechanisms and thus delay emergence of
acquired resistance, compared with tumors treated with
anastrozole alone.
When tolerability was assessed, the AE profile was
similar in all treatment groups, with no emerging safety
concerns for fulvestrant 500 mg. However, only very lim-
ited safety data were available due to the short treatment
duration in the study. The safety profile of fulvestrant
500 mg has previously been described in FIRST and
CONFIRM, where the safety profile of the higher dose
was similar to that of the 250 mg dose. The comparable
AE profile between fulvestrant 500 mg plus anastrozole
and anastrozole alone was in keeping with the side-effect
profiles of fulvestrant 250 mg plus anastrozole versus
anastrozole alone reported in FACT [11]. There were,
therefore, no new safety concerns for the higher-dose ful-
vestrant regimen, when used alone or in combination
with anastrozole [10,13,24].
Conclusions
This is the first direct comparison of a selective ER
antagonist versus an AI, and reported greater down-reg-
ulation of ER with fulvestrant 500 mg compared with
anastrozole. Reductions in Ki67 labeling index and PgR
expression were comparable between the treatment
groups. This study is also the only one thus far to com-
pare fulvestrant 500 mg plus anastrozole versus fulves-
trant 500 mg alone. It demonstrated no additional
reductions in ER, PgR and Ki67 with the combination,
adding to data indicating that combining other types of
anti-estrogen (for example, tamoxifen) with an AI does
not appear to provide additional clinical benefit over an
anti-estrogen alone [25-27].
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